ArticleVeterinary and comparative oncology2013
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma.
Article in Veterinary and comparative oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Canine cutaneous and subcutaneous soft tissue sarcoma in dogs: a consensus report from the Brazilian association of veterinary oncology.Frontiers in veterinary science · 2026Review
- Myeloid Cells in Acute Kidney Injury.Seminars in nephrology · 2025Review
- Assessment of Tumor-Associated Tissue Eosinophilia (TATE) and Tumor-Associated Macrophages (TAMs) in Canine Transitional Cell Carcinoma of the Urinary Bladder.Animals : an open access journal from MDPI · 2024Article
- Depletion of macrophages with clodronate liposomes partially attenuates renal fibrosis on AKI-CKD transition.Renal failure · 2023Article
- Immunopathology of Extracellular Vesicles in Macrophage and Glioma Cross-Talk.Journal of clinical medicine · 2023Review
- Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.Frontiers in immunology · 2023Review
- Article
- Roles of cell fusion, hybridization and polyploid cell formation in cancer metastasis.World journal of clinical oncology · 2020Review
- Article
- A Role for Dogs in Advancing Cancer Immunotherapy Research.Frontiers in immunology · 2019Review
- Targeting macrophages: therapeutic approaches in cancer.Nature reviews. Drug discovery · 2018Review
- Role of monocyte recruitment in hemangiosarcoma metastasis in dogs.Veterinary and comparative oncology · 2017Article
- Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.International journal of molecular sciences · 2016Review
- Manipulation of Innate Immunity for Cancer Therapy in Dogs.Veterinary sciences · 2015Review
- Review
- The importance of comparative oncology in translational medicine.Cancer immunology, immunotherapy : CII · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Increased numbers of tumour-associated macrophages correlate with rapid tumour growth and metastasis in tumours. Thus, macrophage depletion has potential as a novel cancer therapy and positive responses have been reported in rodent tumour models. To investigate the effectiveness of this approach in dogs with cancer, we evaluated the effects of the macrophage-depleting agent liposomal clodronate (LC) in dogs with soft-tissue sarcoma (STS). To this end, we conducted a clinical trial of LC therapy in 13 dogs with STS. Repeated LC administration was well tolerated clinically. Preliminary examination of tumour biopsy sets from 5 of the 13 dogs demonstrated that the density of CD11b(+) macrophages was significantly decreased after LC treatment. Circulating concentrations of interleukin-8 were also significantly reduced. These preliminary studies are the first to suggest that LC can be used as a systemic macrophage-depleting agent in dogs to reduce numbers of tumour-associated macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.